| 维奈克拉联合用药治疗急性髓系白血病的研究进展 |
| |
| 引用本文： | 朱玉,冯悦,罗兴春,刘蓓.维奈克拉联合用药治疗急性髓系白血病的研究进展[J].中国新药与临床杂志,2021(3):161-166. |
| |
| 作者姓名： | 朱玉 冯悦 罗兴春 刘蓓 |
| |
| 作者单位： | 兰州大学第一临床医学院;兰州大学第一医院血液内科 |
| |
| 摘 要： | Bcl-2是调控肿瘤细胞凋亡的关键分子,也是近年研究证实的白血病治疗新靶点。针对该靶点的Bcl-2抑制剂维奈克拉与去甲基化药物的联合用药方案于2018年11月获美国食品和药物管理局批准,用于治疗75岁及以上初治或有合并症不适合高强度化疗的急性髓系白血病(AML)患者。多项研究证实维奈克拉联合去甲基化药物或小分子抑制剂在治疗初治老年AML或复发/难治性AML患者等方面取得显著疗效。
|
| 关 键 词： | 维奈克拉 白血病 髓样 急性 淋巴瘤 B细胞 去甲基化药物 小分子抑制剂 |
Research progress of venetoclax combined with other drugs for acute myeloid leukemia |
| |
| ZHU Yu,FENG Yue,LUO Xing-chun,LIU Bei.Research progress of venetoclax combined with other drugs for acute myeloid leukemia[J].Chinese Journal of New Drugs and Clinical Remedies,2021(3):161-166. |
| |
| Authors: | ZHU Yu FENG Yue LUO Xing-chun LIU Bei |
| |
| Affiliation: | (The First School of Clinical Medicine of Lanzhou University,Lanzhou GANSU 730000,China;Department of Hematology,the First Hospital of Lanzhou University,Lanzhou GANSU 730000,China) |
| |
| Abstract: | Bcl-2 plays a key role in apoptosis process of tumor cells and it is a new target for leukemia.The combination regimen of the Bcl-2 inhibitor venetoclax and hypomethylating agents for this target has been approved by the U.S.Food and Drug Administration in November 2018 for the treatment of newly-diagnosed acute myeloid leukemia(AML)patients who are 75 years or older,or who have complications that are not suitable for high-intensive chemotherapy.Several studies have confired that combination strategies of venetoclax and hypomethylating agents or small-molecule inhibitors have obtained positive results in the treatment of newly diagnosed elderly patients with AML or relapsed/refractory AML. |
| |
| Keywords: | venetoclax leukemia myeloid acute lymphoma B-cell hypomethylating agents small-molecule inhibitors |
| 本文献已被 维普 等数据库收录！ |
